A carregar...

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Hematol
Main Authors: Bewersdorf, Jan Philipp, Carraway, Hetty, Prebet, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7675905/
https://ncbi.nlm.nih.gov/pubmed/33240476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720955006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!